Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith S Kaye

Showing results (41-50 of 421) with videos related to

Pageof 43
Sort By:
Antimicrobial Agents and Chemotherapy|December 24, 2008
Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infectionsRonald P Olson, Lizzie J Harrell, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2015
Optimal Usage of Colistin: Are We Any Closer?Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Antimicrobial Agents and Chemotherapy|May 19, 2010
Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 1Jason M Pogue, Brian A Potoski, Keith S Kaye
International Journal of Antimicrobial Agents|February 4, 2019
Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experienceChristopher J Destache, David J Guervil, Keith S Kaye
Virulence|July 8, 2016
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant EnterobacteriaceaeJoshua T Thaden, Jason M Pogue, Keith S Kaye
International Journal of Antimicrobial Agents|November 24, 2016
Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 30, 2016
Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?Jason M Pogue, Jessica K Ortwine, Keith S Kaye
JAMA|February 11, 2015
Contact precautions for patients with multidrug-resistant pathogens--replyDaniel J Morgan, Keith S Kaye, Daniel J Diekema
Infectious Disease Clinics of North America|December 15, 2019
Collaborative Antimicrobial Stewardship: Working with Hospital and Health System AdministrationWhitney R Buckel, Keith S Kaye, Payal K Patel
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2018
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary ConsiderationsJason M Pogue, Robert A Bonomo, Keith S Kaye
Pageof 43

Showing results (41-50 of 421) with videos related to

Sort By:
Pageof 43
Antimicrobial Agents and Chemotherapy|December 24, 2008
Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infectionsRonald P Olson, Lizzie J Harrell, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 11, 2015
Optimal Usage of Colistin: Are We Any Closer?Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Antimicrobial Agents and Chemotherapy|May 19, 2010
Aminoglycoside use in intensive care units and aminoglycoside nephrotoxicity. Comment letter 1Jason M Pogue, Brian A Potoski, Keith S Kaye
International Journal of Antimicrobial Agents|February 4, 2019
Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experienceChristopher J Destache, David J Guervil, Keith S Kaye
Virulence|July 8, 2016
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant EnterobacteriaceaeJoshua T Thaden, Jason M Pogue, Keith S Kaye
International Journal of Antimicrobial Agents|November 24, 2016
Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?Jason M Pogue, Jessica K Ortwine, Keith S Kaye
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 30, 2016
Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?Jason M Pogue, Jessica K Ortwine, Keith S Kaye
JAMA|February 11, 2015
Contact precautions for patients with multidrug-resistant pathogens--replyDaniel J Morgan, Keith S Kaye, Daniel J Diekema
Infectious Disease Clinics of North America|December 15, 2019
Collaborative Antimicrobial Stewardship: Working with Hospital and Health System AdministrationWhitney R Buckel, Keith S Kaye, Payal K Patel
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2018
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary ConsiderationsJason M Pogue, Robert A Bonomo, Keith S Kaye
Pageof 43